SG11202011549RA - Topical formulations of dgat1 inhibitors and their methods of use - Google Patents
Topical formulations of dgat1 inhibitors and their methods of useInfo
- Publication number
- SG11202011549RA SG11202011549RA SG11202011549RA SG11202011549RA SG11202011549RA SG 11202011549R A SG11202011549R A SG 11202011549RA SG 11202011549R A SG11202011549R A SG 11202011549RA SG 11202011549R A SG11202011549R A SG 11202011549RA SG 11202011549R A SG11202011549R A SG 11202011549RA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- topical formulations
- dgat1 inhibitors
- dgat1
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688180P | 2018-06-21 | 2018-06-21 | |
| US201862695441P | 2018-07-09 | 2018-07-09 | |
| PCT/US2019/038535 WO2019246558A1 (en) | 2018-06-21 | 2019-06-21 | Topical formulations of dgat1 inhibitors and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011549RA true SG11202011549RA (en) | 2020-12-30 |
Family
ID=68984020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011549RA SG11202011549RA (en) | 2018-06-21 | 2019-06-21 | Topical formulations of dgat1 inhibitors and their methods of use |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210260055A1 (en) |
| EP (1) | EP3813836A4 (en) |
| JP (1) | JP2021527634A (en) |
| KR (1) | KR20210022558A (en) |
| CN (1) | CN113194951A (en) |
| AU (1) | AU2019290231A1 (en) |
| BR (1) | BR112020025208A2 (en) |
| CA (1) | CA3101064A1 (en) |
| MX (1) | MX2020013492A (en) |
| SG (1) | SG11202011549RA (en) |
| WO (1) | WO2019246558A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022027086A2 (en) * | 2020-06-30 | 2023-03-14 | Dermira Inc | IRAK4 INHIBITORS AND TOPICAL USES THEREOF |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL357041A1 (en) * | 2000-02-02 | 2004-07-12 | Warner-Lambert Company | Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders |
| CN101541321A (en) * | 2006-09-06 | 2009-09-23 | Isw集团公司 | Topical compositions |
| JP5662803B2 (en) * | 2007-12-20 | 2015-02-04 | アストラゼネカ アクチボラグ | Carbamoyl compounds 190 as DGAT1 inhibitors |
| US9688667B2 (en) * | 2013-12-13 | 2017-06-27 | Sun Pharmaceutical Industries Limited | Tazarotene with low dimer impurity for treating acne or psoriasis |
| AU2015212312A1 (en) * | 2014-01-29 | 2016-08-18 | Vyome Therapeutics Limited | Treatments for resistant acne |
| ES2881706T3 (en) * | 2014-03-12 | 2021-11-30 | Astrazeneca Ab | Treatment method for skin conditions |
| US10226470B2 (en) * | 2014-06-03 | 2019-03-12 | The Board Of Trustees Of The Leland Stanford Junior University | DGAT1 inhibition for treatment of demyelinating inflammatory disease |
| EA035515B1 (en) * | 2016-02-04 | 2020-06-29 | Синдом Фарма, Инк. | Deuterated domperidone compositions and methods for therapy of disorders |
-
2019
- 2019-06-21 CN CN201980039168.4A patent/CN113194951A/en active Pending
- 2019-06-21 SG SG11202011549RA patent/SG11202011549RA/en unknown
- 2019-06-21 WO PCT/US2019/038535 patent/WO2019246558A1/en active Application Filing
- 2019-06-21 KR KR1020207035008A patent/KR20210022558A/en unknown
- 2019-06-21 BR BR112020025208-5A patent/BR112020025208A2/en not_active IP Right Cessation
- 2019-06-21 EP EP19822957.7A patent/EP3813836A4/en not_active Withdrawn
- 2019-06-21 CA CA3101064A patent/CA3101064A1/en active Pending
- 2019-06-21 US US17/253,373 patent/US20210260055A1/en not_active Abandoned
- 2019-06-21 MX MX2020013492A patent/MX2020013492A/en unknown
- 2019-06-21 JP JP2020566961A patent/JP2021527634A/en active Pending
- 2019-06-21 AU AU2019290231A patent/AU2019290231A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019246558A1 (en) | 2019-12-26 |
| CN113194951A (en) | 2021-07-30 |
| CA3101064A1 (en) | 2019-12-26 |
| EP3813836A1 (en) | 2021-05-05 |
| AU2019290231A1 (en) | 2020-12-17 |
| KR20210022558A (en) | 2021-03-03 |
| EP3813836A4 (en) | 2022-03-16 |
| BR112020025208A2 (en) | 2021-03-09 |
| JP2021527634A (en) | 2021-10-14 |
| US20210260055A1 (en) | 2021-08-26 |
| MX2020013492A (en) | 2021-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3700527A4 (en) | Papd5 inhibitors and methods of use thereof | |
| EP3684361A4 (en) | Substituted inhibitors of menin-mll and methods of use | |
| HK1259232A1 (en) | Substituted inhibitors of menin-mll and methods of use | |
| HK1249513A1 (en) | Fused-tricyclic inhibitors of kras and methods of use thereof | |
| EP3510040A4 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| IL283592A (en) | Inhibitors of apol1 and methods of using same | |
| IL267291B (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| IL279475A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| EP3723770A4 (en) | Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use | |
| IL287751A (en) | Kcnt1 inhibitors and methods of use | |
| IL259801A (en) | Inhibitors of ezh2 and methods of use thereof | |
| IL287768A (en) | Kcnt1 inhibitors and methods of use | |
| IL287973A (en) | Acss2 inhibitors and methods of use thereof | |
| IL276711A (en) | Arginase inhibitors and methods of use thereof | |
| IL274504A (en) | Acss2 inhibitors and methods of use thereof | |
| SI4084778T1 (en) | Amorphous kinase inhibitor formulations and methods of use thereof | |
| IL263506A (en) | Topical formulations of pde-4 inhibitors and their methods of use | |
| EP3735242A4 (en) | Metallo-beta-lactamase inhibitors and methods of use thereof | |
| EP3846808A4 (en) | Papd5 inhibitors and methods of use thereof | |
| HUE066903T2 (en) | Arginase inhibitors and methods of use thereof | |
| IL286149A (en) | Caspase inhibitors and methods of use thereof | |
| EP3793552C0 (en) | Abhd12 inhibitors and methods of making and using same | |
| SG11202011549RA (en) | Topical formulations of dgat1 inhibitors and their methods of use | |
| EP3654968A4 (en) | Metallo-beta-lactamase inhibitors and methods of use thereof | |
| HUE065493T2 (en) | Amorphous kinase inhibitor formulations and methods of use thereof |